Contact Lens Insertion and Removal in a Senior Subject Demographic
NCT ID: NCT03597178
Last Updated: 2019-08-28
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
16 participants
INTERVENTIONAL
2018-06-29
2018-07-12
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of Senofilcon A With New UV-blocker on a Neophyte Population
NCT03742271
Evaluation of Electronic LogMar Visual Acuity and Contrast Sensitivity in a Population of Contact Lens Wearers
NCT03222037
Visual Performance of Senofilcon A With and Without a New UV/HEV-filter
NCT05021081
Handling Comparison Between Two Contact Lens Types
NCT02310126
Evaluation of the Performance of Investigational Contact Lenses in a Presbyopic Population
NCT01763047
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DEVICE_FEASIBILITY
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
senofilcon A
Subjects that are of at least 60 years of age and non-habitual contact lens wearers will receive instructions to insert and remove a contact lens from each eye.
senofilcon A
ACUVUE OASYS® 1-DAY with HydraLuxe™ Technology
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
senofilcon A
ACUVUE OASYS® 1-DAY with HydraLuxe™ Technology
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. The subject must read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form.
2. Appear able and willing to adhere to the instructions set forth in this clinical protocol.
3. Must be at least 60 years of age at the time of screening.
4. The subject must have normal eyes (i.e., no ocular medications or infections of any type).
5. The subject must have best corrected visual acuity (BCVA) of 20/30 or better in each eye.
Exclusion Criteria
1. A habitual and adapted wearer of contact lenses (have worn a contact lens at least one time in the past 5 years).
2. Currently pregnant or lactating (subjects who become pregnant during the study will be discontinued).
3. Any systemic disease, autoimmune disease, or use of medication that may interfere with contact lens wear.
4. Any ocular infection.
5. Any corneal distortion resulting from previous hard or rigid gas permeable contact lens wear.
6. Participation in any contact lens or lens care product clinical trial within 14 days prior to study enrollment.
7. History of binocular vision abnormality or strabismus.
8. Any infectious disease (e.g., hepatitis, tuberculosis) or a contagious immunosuppressive disease (e.g., HIV, by self-report).
9. Suspicion of or recent history of alcohol or substance abuse.
10. History of serious mental illness.
11. History of seizures.
12. Employee of investigational clinic (e.g., Investigator, Coordinator, Technician)
13. Any ocular allergies, infections or other ocular abnormalities that are known to interfere with contact lens wear and/or participation in the study. This may include, but not be limited to entropion, ectropion, extrusions, chalazia, recurrent styes, glaucoma, history of recurrent corneal erosions, aphakia, or corneal distortion
14. Any Grade 3 or greater slit lamp findings (e.g., edema, corneal neovascularization, corneal staining, tarsal abnormalities, conjunctival injection) on the FDA classification scale
15. Any previous history or signs of a contact lens-related corneal inflammatory event (e.g., past peripheral ulcer or round peripheral scar), or any other ocular abnormality that may contraindicate contact lens wear.
60 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Johnson & Johnson Vision Care, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Brian Pall, OD, MS, FAAO
Role: STUDY_DIRECTOR
Johnson & Johnson Vision Care, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
VRC-East
Jacksonville, Florida, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CR-6289
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.